Loading
SSTR PET followed by PRRT is the original theranostic pair: the scan with the diagnostic isotope decides who gets the same molecule with the therapeutic isotope.
This diagnostic-therapeutic pairing links somatostatin receptor PET, using gallium-68 or copper-64 DOTATATE, to peptide receptor radionuclide therapy with lutetium-177 dotatate or 177Lu-edotreotide in neuroendocrine tumours. Because the imaging and therapeutic agents share identical peptide chemistry, the biodistribution seen on the scan predicts where the therapy will be delivered, which is the founding logic of theranostics. Every pivotal PRRT trial, including NETTER-1, NETTER-2 and COMPETE, required SSTR-avid disease on imaging, and both the intensity of uptake, graded on the Krenning scale, and the absence of FDG-avid lesions lacking SSTR predict benefit. The same template was later copied by PSMA theranostics in prostate cancer.
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
Shares Theranostics, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate.
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
Shares Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.